ZA966890B - Method for treating substance abuse withdrawal. - Google Patents

Method for treating substance abuse withdrawal.

Info

Publication number
ZA966890B
ZA966890B ZA9606890A ZA966890A ZA966890B ZA 966890 B ZA966890 B ZA 966890B ZA 9606890 A ZA9606890 A ZA 9606890A ZA 966890 A ZA966890 A ZA 966890A ZA 966890 B ZA966890 B ZA 966890B
Authority
ZA
South Africa
Prior art keywords
substance abuse
treating substance
abuse withdrawal
withdrawal
treating
Prior art date
Application number
ZA9606890A
Other languages
English (en)
Inventor
August Masaru Watanabe
Thomas Frank Bumol
Mitchell Irvin Steinberg
Mary Jeanne Kallman
Kurt Rasmussen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA966890B publication Critical patent/ZA966890B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA9606890A 1995-08-15 1996-08-14 Method for treating substance abuse withdrawal. ZA966890B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US234195P 1995-08-15 1995-08-15

Publications (1)

Publication Number Publication Date
ZA966890B true ZA966890B (en) 1998-02-16

Family

ID=21700330

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9606890A ZA966890B (en) 1995-08-15 1996-08-14 Method for treating substance abuse withdrawal.

Country Status (16)

Country Link
US (3) US5732717A (cs)
EP (1) EP0768087A3 (cs)
JP (1) JPH09104626A (cs)
KR (1) KR970009799A (cs)
CN (1) CN1145226A (cs)
AU (1) AU6207896A (cs)
BR (1) BR9603431A (cs)
CA (1) CA2182851A1 (cs)
CZ (1) CZ237896A3 (cs)
HU (1) HUP9602215A3 (cs)
IL (1) IL119037A0 (cs)
NO (1) NO963322L (cs)
PL (1) PL315653A1 (cs)
SG (1) SG52832A1 (cs)
YU (1) YU46496A (cs)
ZA (1) ZA966890B (cs)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11501020A (ja) * 1995-02-28 1999-01-26 バイエルスドルフ リリー ゲゼルシャフト ミット ベシュレンクテル ハフツング アテローム性動脈硬化症を治療するためのモキソニジンの使用
US6093419A (en) * 1995-06-07 2000-07-25 Lectec Corporation Compliance verification method and device in compulsory drug administration
TR199802496T2 (xx) * 1996-06-06 1999-02-22 Eli Lilly And Company Konjestif kalp yetmezli�ini tedavi i�in form�lasyon.
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US8052982B2 (en) 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
US6121289A (en) * 1998-10-09 2000-09-19 Theramax, Inc. Method for enhanced brain delivery of nicotinic antagonist
ID29943A (id) * 1998-10-30 2001-10-25 Daiichi Seiyaku Co Senyawa dds dan metode pengukurannya
DE19911371A1 (de) * 1999-03-15 2000-09-21 Solvay Pharm Gmbh Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen
EP1237544A1 (en) * 1999-12-16 2002-09-11 Trident Technologies, LLC System and method for extended delivery of a therapeutic agent with its receptor loading dose
AU3846801A (en) 2000-02-16 2001-08-27 Brigham & Womens Hospital Aspirin-triggered lipid mediators
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
WO2003053423A2 (en) * 2001-12-18 2003-07-03 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
CA2472188C (en) * 2002-01-18 2011-06-21 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
US7902257B2 (en) 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US6933275B2 (en) * 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
NZ536965A (en) * 2002-05-31 2007-02-23 Titan Pharmaceuticals Inc Nonerodible polymeric matrix with buprenorphine encapsulated for the treatment of opiate addiction and pain
PL372695A1 (en) * 2002-06-19 2005-07-25 Solvay Pharmaceuticals Gmbh Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
US7759395B2 (en) * 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
CA2495260C (en) * 2002-08-12 2012-05-29 Brigham And Women's Hospital Resolvins: biotemplates for novel therapeutic interventions
WO2004078143A2 (en) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
MXPA05010450A (es) * 2003-03-31 2005-11-04 Titan Pharmaceuticals Inc Dispositivo polimerico implantable para la liberacion prolongada de agonistas de dopamina.
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20050095279A1 (en) * 2003-10-30 2005-05-05 Gale Robert M. Transdermal analgesic systems having reduced abuse potential
WO2005099705A2 (en) * 2004-03-24 2005-10-27 Bayer Pharmaceuticals Corporation Preparation of imidazole derivatives and methods of use
EP1755537A4 (en) * 2004-04-14 2009-12-09 Univ Boston METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING PERIODONTOPATHIA
WO2007041440A2 (en) 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
EP1954291A1 (en) * 2005-11-18 2008-08-13 Trustees Of Boston University Treatment and prevention of bone loss using resolvins
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
EP2095814A1 (de) * 2008-02-26 2009-09-02 Wolfgang J. Kox Medikamentengestützter Nikotinentzug
RU2485954C1 (ru) * 2012-02-29 2013-06-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" РАМН Средство для купирования абстинентного синдрома при зависимости от опиатов
EP3866898A4 (en) * 2018-10-19 2022-07-20 Shalon Ventures Research, LLC PERSONALIZED DRUG DISPENSER AND PROCEDURE

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201211A (en) * 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
US4255439A (en) * 1979-07-13 1981-03-10 Irving Cooper Means and method for aiding individuals to stop smoking
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4382946A (en) * 1981-12-14 1983-05-10 Merrell Dow Pharmaceuticals Inc. Method of alleviating withdrawal symptoms
US4575510A (en) * 1983-02-17 1986-03-11 Merrell Dow Pharmaceuticals Inc. Method of alleviating withdrawal symptoms
US4555397A (en) * 1983-08-12 1985-11-26 Nicholas Bachynsky Method for anti-cholinergic blockage of withdrawal symptoms in smoking cessation
US4783456A (en) * 1984-03-02 1988-11-08 Research Foundation For Mental Hygiene, Inc. Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking
US4588739A (en) * 1984-03-02 1986-05-13 Research Foundation For Mental Hygiene, Inc. Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking
US4683231A (en) * 1984-03-02 1987-07-28 Research Foundation For Mental Hygiene, Inc. Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
DE3729299A1 (de) * 1987-09-02 1989-03-23 Beiersdorf Ag Transdermales therapeutisches system
DE3739779A1 (de) * 1987-11-24 1989-06-08 Beiersdorf Ag Pharmazeutische praeparate
US4788189A (en) * 1988-02-29 1988-11-29 Glazer Howard I Method to treat smoking withdrawal symptoms by potentiated central noradrenergic blocking
US4956391A (en) * 1988-08-17 1990-09-11 Sapse Alfred T Protected complex of procaine for the treatment of symptoms from narcotics addiction, tinnitus and alzheimer's disease
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
US5051426A (en) * 1990-03-27 1991-09-24 Parnell Pharmaceuticals, Inc. Method for effecting withdrawal from drug dependency
US5234947A (en) * 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time

Also Published As

Publication number Publication date
NO963322D0 (no) 1996-08-09
YU46496A (sh) 1999-09-27
EP0768087A3 (en) 2000-01-26
SG52832A1 (en) 1998-09-28
US5846974A (en) 1998-12-08
KR970009799A (ko) 1997-03-27
HUP9602215A3 (en) 2000-07-28
CN1145226A (zh) 1997-03-19
US5732717A (en) 1998-03-31
JPH09104626A (ja) 1997-04-22
CZ237896A3 (en) 1997-03-12
CA2182851A1 (en) 1997-02-16
HUP9602215A2 (hu) 1998-09-28
HU9602215D0 (en) 1996-10-28
AU6207896A (en) 1997-02-20
NO963322L (no) 1997-02-17
MX9603341A (es) 1997-07-31
PL315653A1 (en) 1997-02-17
EP0768087A2 (en) 1997-04-16
BR9603431A (pt) 1998-05-12
US5816260A (en) 1998-10-06
IL119037A0 (en) 1996-11-14

Similar Documents

Publication Publication Date Title
ZA966890B (en) Method for treating substance abuse withdrawal.
IL122718A0 (en) Methods for treating diabetes
ZA961316B (en) Benzopyran-containing compounds and method for their use.
IL126203A0 (en) Method for treating pain
EP0906104A4 (en) PAIN TREATMENT PROCESS
ZA973707B (en) Method for treating inflammation.
ZA966202B (en) Drawing method and apparatus.
ZA96548B (en) Method for treating drug addiction
ZA971772B (en) Process for treating wood.
IL125031A0 (en) Method for treating depression
IL126064A0 (en) Method for treating pain
ZA963108B (en) Method for treating nicotine withdrawal.
EP0677934A3 (fr) Procédé de détection d'un motif dans une transmission série.
IL124786A0 (en) Method for treating pain
AU3896597A (en) Method for treating substance abuse
ZA971899B (en) Method for treating insomnia
EP0608906A3 (en) Apparatus and method for treating hosiery articles.
AU3896497A (en) Method for treating nicotine withdrawal
EP0667175A3 (de) Verfahren zur Bearbeitung von Stahlkanten für Ski od. dgl.
GB9606617D0 (en) Method for treating substance abuse
EP0763802A3 (de) Verfahren zur psychometrischen Authentierung
ZA972236B (en) Method and device for treating boards.
GB9606614D0 (en) Method for treating obsessive-compulsive disorder
AU2198997A (en) Method for treating insomnia
EP0735180A3 (de) Verfahren zur Behandlung von Cellulose enthaltenden Geweben